Ammar Almasalkhi, MD
Sleep Medicine · Louisville, KYNPI 1447230651
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.9%), food and beverage and education — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 80.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $1,134 and has fallen 81.0% since, to $215 in 2025.
Across 24 payments — averaging $69.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$1K
- Lilly USA, LLC$95
- Sanofi-aventis U.S. LLC$79
- United Therapeutics Corporation$33
- Mylan Specialty L.p.$31
- Boehringer Ingelheim$25
- plus $65 from 4 others
What the payments were for
- Travel & lodging$94857%
- Food & beverage$61437%
- Education$976%
- Gifts$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 12 | $1,339 |
| Lilly USA, LLC | 1 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| United Therapeutics Corporation | 2 | $33 |
| Mylan Specialty L.p. | 2 | $31 |
| Boehringer Ingelheim | 2 | $25 |
| GSK | 1 | $20 |
| Insmed, Inc. | 1 | $18 |
| AstraZeneca | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,665 in reported general payments places this provider in the 55th percentile of 28 sleep medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 21 | $269,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $64,454 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $31,564 |
| Spiriva RespimatTiotropium Bromide | 26 | $21,907 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $11,962 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $8,018 |
| Albuterol Sulfate | 15 | $7,268 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $6,810 |
| Modafinil | 32 | $6,504 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $5,975 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 103 | $3,298 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,687 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,019 |
| Ventolin HfaAlbuterol Sulfate | 34 | $1,848 |
| Eszopiclone | 73 | $1,503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $25 | $291,90447 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $20 | $104,036144 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $14 | $17,93744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 28 sleep medicine providers in Kentucky.
Other sleep medicine in Louisville
- Kevin TriceLouisville$220K
- William LacyLouisville$6K
- Robert KarmanLouisville$3K
- Egambaram SenthilvelLouisville$2K
- Juhee MianLouisville$2K
- Nicole ToddLouisville$2K
- Sarika ChandiramaniLouisville$2K
- Warren ShaikunLouisville$1K
- Rajanna RamaswamyLouisville$1K
- Courtney MinorLouisville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.